Company news
Nurexone Biologic Inc (TSXV:NRX) news
Every Nurexone Biologic Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
September 14, 2026
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
August 31, 2026
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
August 28, 2026
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
August 21, 2026
NurExone Announces Closing of C$1,066,078 Private Placement
August 20, 2026
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
August 14, 2026
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
August 12, 2026
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
July 30, 2026
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
July 28, 2026
NurExone Announces Closing of Non-Brokered Private Placement
June 30, 2026
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
June 24, 2026
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
June 1, 2026
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
May 19, 2026
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
May 14, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
April 27, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
April 16, 2026
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026
April 10, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
April 7, 2026
NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
April 7, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
April 1, 2026
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
March 26, 2026
NurExone Announces Corporate Updates
March 11, 2026
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
February 27, 2026
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
February 10, 2026
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
January 30, 2026
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
December 19, 2025
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
December 12, 2025
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 28, 2025
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
November 12, 2025
NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
November 3, 2025
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
November 3, 2025
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
October 21, 2025
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
October 8, 2025
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
September 16, 2025
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
September 11, 2025
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
September 8, 2025
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
August 28, 2025
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
August 20, 2025
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
August 8, 2025
NurExone's Exosomes Show Stronger Healing Potential Than Industry Standard
August 8, 2025
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
July 25, 2025
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World's Most Promising Science-Based Start-Ups
July 25, 2025
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
July 8, 2025
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
June 20, 2025
NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
June 4, 2025
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
May 30, 2025
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 27, 2025
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
May 8, 2025
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
May 2, 2025
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
April 24, 2025